Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Complete Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Trial Phase: I/II
Investigator: Elizabeth Loggers
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
Keywords:
- Melanoma
- Sarcoma
- Solid Tumors
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Sarcoma, Synovial
- Liposarcoma
- Sarcoma, Ewing
- Osteosarcoma
- Sarcoma, Soft Tissue
- Leiomyosarcoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
I/II
Elizabeth Loggers
RG1121371
NCT03425279
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Melanoma
Sarcoma
Solid Tumors
Lung Carcinoma, Non-Small-Cell (NSCLC)
Sarcoma, Synovial
Liposarcoma
Sarcoma, Ewing
Osteosarcoma
Sarcoma, Soft Tissue
Leiomyosarcoma